Research

Hormonal

GLP-1 receptor agonists (Liraglutid, Semaglutid) and dual agonists (Tirzepatid) produce significant weight loss (16-20%) and reduce cardiovascular/renal complications in Type 2 Diabetes, but their long-term efficacy and cost-effectiveness remain unproven.

If lifestyle changes are insufficient, GLP-1 drugs like Semaglutid offer significant weight loss (up to 20%) and heart/kidney benefits, especially for diabetics. However, they are expensive, require injections, and likely need to be taken indefinitely to maintain weight loss. Discuss cost and long-term commitment with your doctor.

GoodQualifiesHIGH confidence
Liraglutid führte im Vergleich zu Placebo in gross angelegten Studien zu durchschnittlich 16 % Gewichtsabnahme... Semaglutid... bewirkte nach 1 ½ Jahren eine recht eindrucksvolle 20%ige Gewichtsreduktion... Es ist anzunehmen, dass nach Absetzen der Behandlung das Gewicht wieder ansteigt.
Ulrich Keller · 2022

Why this rating

Based on cited meta-analyses and RCTs (STEP 8, etc.), though the editorial itself is an opinion piece.

Source

New obesity drug therapies – what is the added value?

Ulrich Keller · 2022

DOI 10.36000/hbt.2022.07.002

narrative_review
Read the paper
DOI resolved against Crossref · corpus check 2026-06-10

This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →